Pharmaceutical Manufacturing Flooring

Pharmaceutical flooring is a different specification problem than food and beverage even though both reference FDA standards. The chemistry, the cleaning protocols, and the validation requirements all diverge from the F&B vertical, and a floor system that holds up in one will fail in the other. Standard epoxy degrades under continuous 70% IPA sanitation within twelve to eighteen months — yellowing, chalking, softening at the surface — and tile grout in a sterile suite absorbs IPA and harbors spores that bacterial swabs and environmental monitoring will find. Vinyl sheet flooring fails at the welded seams. Cementitious urethane handles the pharma chemistry stack because the urethane-mortar matrix is solvent-resistant in continuous exposure, not just incidental contact. The seamless monolithic construction with integral cove base meets the cleanability and harborage-free requirements that cGMP, USP <797>, USP <800>, and ISO 14644 environments all need from the floor.

The compliance framework drives the spec. FDA cGMP — 21 CFR Parts 210 and 211 for pharmaceuticals, Part 820 for medical devices — sets the baseline for cleanable, non-porous, validatable flooring in manufacturing areas. USP <797> governs sterile compounding pharmacies. USP <800> covers handling of hazardous drugs. ISO 14644 classifies cleanrooms from Class 5 (Grade A) through Class 8 (Grade D), each class driving its own floor surface, particle, and cleanability requirements. UC works across the full classification range, with system thickness specified by zone — 3/16″ slurry in Class 5 sterile corridors where particle generation is the primary concern, 1/4″ mortar in Class 7-8 processing suites with daily IPA and quat sanitizer exposure, and 3/8″ heavy-duty mortar where mechanical loads from compression presses, coating pans, or material handling equipment are part of the operating reality.

Validation documentation is what separates pharma flooring from any other vertical. cGMP facilities require IQ/OQ/PQ qualification of the installed floor system — installation qualification documenting that the floor was placed to manufacturer specification, operational qualification proving the floor meets its performance criteria, and performance qualification confirming the floor holds up under production conditions. Surface profile records, ASTM F2170 moisture readings, manufacturer batch numbers, cure documentation, integral cove base radius and height, and any cleanroom particle-generation testing all go into the closeout package. Validation documentation is not optional the way it is in food processing — it is a regulatory submission requirement and one of the first things FDA investigators look for during a facility inspection.

Craftsman has been installing industrial flooring since 1999. Pharmaceutical projects across solid dose manufacturing — weighing, dispensing, granulation, compression, coating, and packaging — and across sterile fill/finish suites, biotech cell culture rooms, vivariums, gowning rooms, and warehouse staging. In-house W-2 crews mobilize nationwide. Surface prep is shot blast or diamond grind to ICRI 310.2 CSP 4-5, with cleanroom particle-containment protocols followed where the work happens inside a controlled-environment building envelope. Slab moisture is verified with ASTM F2170 in-situ probes before primer goes down. Installation runs 3-5 days per area, with foot traffic returning at 12-24 hours and full chemical service within 72 hours of final coat. Pricing for pharma UC installations typically lands at the upper end of the $8-15/sqft installed range, with IQ/OQ/PQ validation documentation scoped and quoted separately.